Syneos Health

Syneos Health is a United States-based professional-services company that provides contract research, clinical development, medical affairs, commercialization, and related consulting services to pharmaceutical and biotechnology companies. Its business model is built around supporting clients across the later stages of the healthcare product life cycle: designing and managing clinical studies, preparing therapies for launch, communicating scientific evidence, and helping commercial organizations reach healthcare professionals and patients. The modern company was created through the combination of two large healthcare-services platforms, INC Research and InVentiv Health. Both organizations themselves grew through acquisitions and consolidation in clinical research, healthcare communications, marketing, patient-support, and commercialization services. Through the InVentiv lineage, Syneos Health can be traced to Snyder Communications, which developed a healthcare-services division during the 1990s. That division became Ventiv Health as an independent company in 1999, later expanded through acquisitions, and adopted the InVentiv Health name after the acquisition of InChord Communications in 2005. INC Research was another major contract research platform and became the other principal constituent of the present company. The Syneos Health name was introduced in January 2018, following the combination of INC Research and InVentiv Health. The rebranding expressed the company’s strategy of integrating clinical-development capabilities with commercial and medical services rather than operating as a narrowly defined clinical-trial contractor. Its clinical-services activities include study planning, trial management, site and investigator support, data-related services, regulatory support, and other functions used in the development of medicines and healthcare products. Its commercial-services activities include product-launch support, marketing, medical communications, field services, market access-related work, and patient or adherence programs where applicable. The company has served clients across multiple therapeutic and geographic markets. Its late-stage clinical focus has made it a partner for pharmaceutical and biotechnology companies seeking external operational capacity for pivotal studies and commercialization programs. In 2022, clinical services accounted for approximately three-quarters of the company’s revenue, while commercial services represented the remaining quarter. The business employed approximately 28,000 people in 110 countries at the end of 2022, according to the cited reference material. Syneos Health was publicly traded on Nasdaq under the symbol SYNH from 2018 until its acquisition by an investor consortium led by Elliott Investment Management, Patient Square Capital, and Veritas Capital. The transaction was announced in May 2023 and completed on September 30, 2023, making the company privately held. Leadership subsequently changed in October 2024, when Costa Panagos was appointed chief executive officer. The company also pursued technology-enabled clinical-development initiatives, including a multi-year collaboration announced in 2023 with Microsoft Research concerning machine-learning tools for clinical-trial optimization. Syneos Health’s positioning rests on the integration of clinical and commercial expertise. Rather than presenting itself solely as a trial-management provider or solely as a healthcare-marketing agency, it offers a connected set of services intended to help clients move treatments from development through launch and market support. Its scale, international delivery network, and combination of research and commercialization capabilities are central to that proposition.

Syneos Health emerged from the consolidation of healthcare-services and contract-research businesses that developed over several decades. One important predecessor line began with Snyder Communications, founded by Daniel M. Snyder in the 1980s. After becoming a public company, Snyder Communications established Snyder Healthcare in 1997 and expanded its healthcare portfolio through acquisitions in the United States and several European countries, including the United Kingdom, France, Germany, Ireland, the Netherlands, and Hungary. In September 1999, Snyder Healthcare was separated from Snyder Communications and became Ventiv Health Inc. Shareholders received Ventiv shares as part of the separation, and Eran Broshy became chief executive officer. Ventiv traded on Nasdaq and continued building a healthcare-services platform. In 2005, it acquired InChord Communications, a healthcare marketing agency headquartered in Westerville, Ohio, in a transaction reported at $185 million. Following that acquisition, the company adopted the InVentiv Health name. In 2006, InVentiv became part of the S&P 600 and acquired Adheris for $60 million. Adheris provided programs intended to support persistence and compliance with prescribed treatments. In 2010, InVentiv Health was taken private by Thomas H. Lee Partners in a transaction estimated at approximately $1.1 billion. The company continued to operate as a diversified healthcare-services provider, combining communications, marketing, patient-support, and other services connected with pharmaceutical products. INC Research developed separately as a contract research organization serving pharmaceutical and biotechnology clients. In 2017, INC Research announced plans to acquire InVentiv Health. The combination joined a clinical-development organization with a healthcare-commercialization and communications platform. In January 2018, the combined company adopted the Syneos Health name and began trading under the Nasdaq symbol SYNH. The new identity emphasized an integrated model spanning clinical development and commercialization. The company’s clinical-services business became its larger operating segment. It supported pharmaceutical and biotechnology clients with clinical trials, particularly later-stage studies, while its commercial-services business provided marketing, medical-affairs, communications, and launch-related support. The combination was intended to give clients access to a broader set of capabilities from development through commercialization rather than requiring separate providers for research and commercial work. In February 2019, Syneos Health reported that the SEC had opened an investigation into its accounting policies. Its 2018 fourth-quarter and full-year reporting was delayed. The matter is a significant governance event in the company’s public-market history, although the available reference material does not provide a final disposition or a quantified financial impact. The COVID-19 pandemic created additional demand for clinical-development capacity as pharmaceutical and biotechnology companies accelerated work on vaccines and medicines. Syneos Health reported strong business conditions during 2020 and 2021, with the company’s cited revenue figures increasing from $4.42 billion in 2020 to $5.21 billion in 2021 and $5.39 billion in 2022. These figures require period-specific financial sourcing and are retained here as historical reference points rather than current financial guidance. In April 2022, Michelle Keefe became chief executive officer, succeeding Alistair Macdonald, who had led the company since 2017. In March 2023, Syneos Health announced a multi-year collaboration with Microsoft Research to explore machine-learning applications for clinical-trial optimization. Later that year, an investor consortium consisting of Elliott Investment Management, Patient Square Capital, and Veritas Capital agreed to acquire the company. The transaction was announced in May 2023 and completed on September 30, 2023, taking Syneos Health private. Costa Panagos was appointed chief executive officer on October 9, 2024. The company remains an active global provider of integrated clinical and commercial services.

1. 2024Costa Panagos appointed CEO

   Costa Panagos was appointed chief executive officer on October 9.

   Source
2. 2023Microsoft Research collaboration announced

   Syneos Health announced a multi-year collaboration with Microsoft Research involving machine learning and clinical-trial optimization.

   Source
3. 2023Company taken private

   A consortium led by Elliott Investment Management, Patient Square Capital, and Veritas Capital completed its acquisition of Syneos Health on September 30.

   Source
4. 2022Michelle Keefe became CEO

   Michelle Keefe succeeded Alistair Macdonald as chief executive officer.

   Source
5. 2019SEC accounting investigation disclosed

   The company reported an SEC investigation into accounting policies and delayed certain 2018 financial reports.

   Source
6. 2018Syneos Health name introduced

   The combined company adopted the Syneos Health name and Nasdaq ticker SYNH in January.

   Source
7. 2017INC Research announced combination with InVentiv Health

   The planned combination brought together a contract research organization and a healthcare commercialization platform.

   Source
8. 2010InVentiv Health taken private

   Thomas H. Lee Partners acquired InVentiv Health in a transaction estimated at approximately $1.1 billion.

   Source
9. 2006Adheris acquired

   InVentiv acquired Adheris, a provider of patient persistence and treatment-compliance programs.

   Source
10. 2005Acquisition of InChord Communications

    Ventiv acquired the healthcare marketing agency InChord Communications and subsequently adopted the InVentiv Health name.

    Source
11. 1999Ventiv Health became an independent company

    Snyder Healthcare was spun off as Ventiv Health Inc., with Eran Broshy appointed chief executive officer.

    Source
12. 1997Snyder Healthcare established

    Snyder Communications created a healthcare-services division that later contributed to the InVentiv Health and Syneos Health predecessor lineage.

    Source

An integrated contract research and commercialization partner combining clinical-development, medical-affairs, healthcare communications, and commercial services.

• Clinical research servicesContract research

  Syneos Health provides outsourced clinical-development support for pharmaceutical and biotechnology companies. Services can include trial planning, operational management, site and investigator support, patient-related activities, data services, and other functions required to conduct clinical studies. The company has particularly emphasized later-stage and pivotal development programs, where sponsors often require substantial global operational capacity.

• Commercial servicesHealthcare commercialization

  The commercial-services business supports the market preparation and ongoing promotion of healthcare products. Its scope includes commercialization strategy, product-launch support, marketing, field services, healthcare communications, and related execution. This capability differentiates Syneos Health from providers focused exclusively on clinical trials.

• Medical affairs and scientific communicationsMedical affairs

  Syneos Health offers services intended to help clients communicate clinical and scientific evidence to healthcare professionals and other stakeholders. These activities form part of the company’s broader medical-affairs and commercialization offering and can support products before and after market launch.

• Patient persistence and adherence programsPatient services

  Through the Adheris predecessor business, the company developed programs aimed at supporting patient persistence and compliance with prescribed treatment. These services reflect the broader healthcare-services heritage of the InVentiv Health platform.

• Machine-learning clinical-trial optimization platform collaborationClinical technology2023

  In 2023, Syneos Health announced a multi-year collaboration with Microsoft Research focused on applying machine learning to the optimization of clinical trials. The initiative represents the company’s technology-oriented approach to improving trial design and execution.

• 2023Announced machine-learning collaboration with Microsoft ResearchOther

  Clinical-trial sponsors increasingly sought technology to improve trial design, execution, and operational efficiency.

  What changed. Syneos Health entered a multi-year collaboration with Microsoft Research to explore machine-learning applications for clinical-trial optimization.

  Aftermath. The initiative expanded the company’s technology-related clinical-development agenda, although the available material does not describe a commercial launch or measured results.

  Source
• 2023Approved and completed take-private transactionM&A

  Syneos Health was a Nasdaq-listed clinical and commercial services company when an investor consortium proposed its acquisition.

  What changed. Elliott Investment Management, Patient Square Capital, and Veritas Capital agreed to acquire the company. The transaction closed on September 30, 2023.

  Aftermath. Syneos Health became privately held and ceased to operate as a Nasdaq-listed company.

  Announced transaction value. $4.46 billion equity value; approximately $7.1 billion including debt (Announced May 2023; completed September 30, 2023)

  Source
• 2018Adopted the Syneos Health identityStrategy

  INC Research and InVentiv Health had combined two complementary healthcare-services platforms: clinical research and commercialization.

  What changed. The combined company adopted Syneos Health as its name and used the Nasdaq symbol SYNH.

  Aftermath. The new identity positioned the company as an integrated clinical-development and commercial-services provider.

  Source

• 2019SEC investigation into accounting policiesControversy

  Syneos Health disclosed that the Securities and Exchange Commission had begun an investigation into the company’s accounting policies. The company delayed its 2018 fourth-quarter and year-end reporting. The available reference material does not establish a final outcome or quantify any resulting penalty.

  Source

• 2024Costa Panagos appointed chief executive officer

  Costa Panagos became chief executive officer on October 9, 2024.

  Leadership change
  Source
• 2023Syneos Health and Microsoft Research announced clinical-trial technology collaboration

  The companies announced a multi-year collaboration focused on using machine learning to support optimization of clinical trials.

  Product launchOther
  Source
• 2023Investor consortium agreed to take Syneos Health private

  Elliott Investment Management, Patient Square Capital, and Veritas Capital agreed to acquire Syneos Health in a transaction announced at approximately $4.46 billion in equity value and approximately $7.1 billion including debt.

  M&A
  Source
• 2023Take-private transaction was completed

  The acquisition of Syneos Health by the investor consortium closed on September 30, 2023, ending the company’s Nasdaq-listed period.

  M&A
  Source
• 2022Syneos Health appointed Michelle Keefe as chief executive officer

  Michelle Keefe, who had previously spent approximately two decades at Pfizer, succeeded Alistair Macdonald as chief executive officer.

  Leadership change
  Source
• 2020Pandemic increased demand for clinical-development services

  The global effort to develop COVID-19 vaccines and medicines increased demand for clinical research and related development capacity, benefiting the company’s business environment during 2020 and 2021.

  Other
  Source

1. Syneos Health
2. Syneos Health official website